info
Google Groups no longer supports new Usenet posts or subscriptions. Historical content remains viewable.
Dismiss
Intranasal Iron Chelator
25 views
Skip to first unread message
ironjustice
Nov 5, 2021, 8:37:39 AM11/5/21
to
Mechanisms of Intranasal Deferoxamine in Neurodegenerative and Neurovascular Disease
Jacob Kosyakovsky 1 2, Jared M Fine 2, William H Frey 2nd 2, Leah R Hanson 2
Review Pharmaceuticals (Basel)
. 2021 Jan 27;14(2):95. doi: 10.3390/ph14020095.
PMID: 33513737 PMCID: PMC7911954 DOI: 10.3390/ph14020095
Free PMC article
Abstract
Identifying disease-modifying therapies for neurological diseases remains one of the greatest gaps in modern medicine. Herein, we present the rationale for intranasal (IN) delivery of deferoxamine (DFO), a high-affinity iron chelator, as a treatment for neurodegenerative and neurovascular disease with a focus on its novel mechanisms. Brain iron dyshomeostasis with iron accumulation is a known feature of brain aging and is implicated in the pathogenesis of a number of neurological diseases. A substantial body of preclinical evidence and early clinical data has demonstrated that IN DFO and other iron chelators have strong disease-modifying impacts in Alzheimer's disease (AD), Parkinson's disease (PD), ischemic stroke, and intracranial hemorrhage (ICH). Acting by the disease-nonspecific pathway of iron chelation, DFO targets each of these complex diseases via multifactorial mechanisms. Accumulating lines of evidence suggest further mechanisms by which IN DFO may also be beneficial in cognitive aging, multiple sclerosis, traumatic brain injury, other neurodegenerative diseases, and vascular dementia. Considering its known safety profile, targeted delivery method, robust preclinical efficacy, multiple mechanisms, and potential applicability across many neurological diseases, the case for further development of IN DFO is considerable.
Keywords: Alzheimer’s disease; Parkinson’s disease; brain iron dyshomeostasis; deferoxamine; intracranial hemorrhage; intranasal; iron chelation; ischemic stroke.
Conflict of interest statement
W.H.F.II and L.R.H. are inventors on a patent owned by HealthPartners Institute related to intranasal deferoxamine. J.K. and J.M.F. have no competing interests.
Who loves ya.
Tom
Jesus Was A Vegetarian!
http://tinyurl.com/2r2nkh
Man Is A Herbivore!
http://tinyurl.com/4rq595
DEAD PEOPLE WALKING
http://tinyurl.com/zk9fk
Jacob Kosyakovsky 1 2, Jared M Fine 2, William H Frey 2nd 2, Leah R Hanson 2
Review Pharmaceuticals (Basel)
. 2021 Jan 27;14(2):95. doi: 10.3390/ph14020095.
PMID: 33513737 PMCID: PMC7911954 DOI: 10.3390/ph14020095
Free PMC article
Abstract
Identifying disease-modifying therapies for neurological diseases remains one of the greatest gaps in modern medicine. Herein, we present the rationale for intranasal (IN) delivery of deferoxamine (DFO), a high-affinity iron chelator, as a treatment for neurodegenerative and neurovascular disease with a focus on its novel mechanisms. Brain iron dyshomeostasis with iron accumulation is a known feature of brain aging and is implicated in the pathogenesis of a number of neurological diseases. A substantial body of preclinical evidence and early clinical data has demonstrated that IN DFO and other iron chelators have strong disease-modifying impacts in Alzheimer's disease (AD), Parkinson's disease (PD), ischemic stroke, and intracranial hemorrhage (ICH). Acting by the disease-nonspecific pathway of iron chelation, DFO targets each of these complex diseases via multifactorial mechanisms. Accumulating lines of evidence suggest further mechanisms by which IN DFO may also be beneficial in cognitive aging, multiple sclerosis, traumatic brain injury, other neurodegenerative diseases, and vascular dementia. Considering its known safety profile, targeted delivery method, robust preclinical efficacy, multiple mechanisms, and potential applicability across many neurological diseases, the case for further development of IN DFO is considerable.
Keywords: Alzheimer’s disease; Parkinson’s disease; brain iron dyshomeostasis; deferoxamine; intracranial hemorrhage; intranasal; iron chelation; ischemic stroke.
Conflict of interest statement
W.H.F.II and L.R.H. are inventors on a patent owned by HealthPartners Institute related to intranasal deferoxamine. J.K. and J.M.F. have no competing interests.
Who loves ya.
Tom
Jesus Was A Vegetarian!
http://tinyurl.com/2r2nkh
Man Is A Herbivore!
http://tinyurl.com/4rq595
DEAD PEOPLE WALKING
http://tinyurl.com/zk9fk
0 new messages